Cargando…
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies
Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and developmental delay/regression, and include Dravet syndrome and Lennox–Gastaut syndrome (LGS). Rufinamide, fenfluramine, stiripentol, cannabidiol...
Autor principal: | Sills, Graeme J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467199/ https://www.ncbi.nlm.nih.gov/pubmed/37655228 http://dx.doi.org/10.1177/17562864231191000 |
Ejemplares similares
-
Inherited Developmental and Epileptic Encephalopathies
por: Bartolini, Emanuele
Publicado: (2021) -
An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
por: Martin, Parthena, et al.
Publicado: (2021) -
Response to antiseizure medications in epileptic patients with malformation of cortical development
por: Chen, Wei, et al.
Publicado: (2021) -
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
por: Strzelczyk, Adam, et al.
Publicado: (2022) -
Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster
por: Takai, Akari, et al.
Publicado: (2020)